Key takeaways
- GLP-1 medications treat biology — appetite signaling, satiety, "food noise" — not willpower. For most patients the problem was never effort.1
- Approved criteria: BMI ≥30, or ≥27 with at least one weight-related condition, always alongside a reduced-calorie diet and increased activity — the indication itself assumes a program.2
- In pivotal trials, semaglutide 2.4 mg produced ~15% average weight loss and tirzepatide up to ~21% at the highest dose over 72 weeks. Individual results vary widely.1,3
- The right dose is the lowest one that works — not the maximum. Escalation should follow response and side effects, not a fixed calendar.2
- A meaningful share of rapidly lost weight can be lean mass. Protein targets and resistance training are not optional extras.1
- Stopping without a maintenance plan is typically followed by substantial regain. Obesity behaves as a chronic disease, and the plan should treat it as one.5,6
For many patients, the issue was never a lack of discipline. It was appetite signaling, satiety hormones, insulin resistance, sleep, stress, and metabolic adaptation — biology that out-negotiated every diet. GLP-1 medications changed that conversation, and they deserve the attention they get.
But the medication is one component of treatment, not the treatment. The difference between "lost weight on an injection" and "became metabolically healthier and kept it" is the program wrapped around the prescription. That is what this page describes.
What these medications are
GLP-1 receptor agonists mimic incretin hormones involved in blood-sugar regulation, appetite, satiety, and gastric emptying. Semaglutide (Wegovy for weight management) is a GLP-1 receptor agonist; tirzepatide (Zepbound for weight management) acts on both GIP and GLP-1 pathways. Both are once-weekly injections, and since December 2025 an oral form of semaglutide has also been FDA-approved for weight management — the first GLP-1 pill for this use.1,3,7 If you are weighing the two main molecules against each other, we compare them directly in semaglutide vs tirzepatide.
Who qualifies
The FDA-approved criteria for tirzepatide (Zepbound) describe adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related condition — high blood pressure, type 2 diabetes, high cholesterol, sleep apnea, and similar — in combination with a reduced-calorie diet and increased physical activity.2 Semaglutide's weight-management criteria are analogous.
BMI qualifies you on paper. A medical evaluation decides whether treatment is actually right: waist circumference, blood pressure, A1c and fasting insulin, lipids, liver enzymes, sleep apnea risk, medications, eating patterns and eating-disorder history, prior weight-loss attempts, muscle mass, pregnancy plans, and personal goals all belong in that decision.
What results to expect
In STEP 1, semaglutide 2.4 mg produced an average weight loss of about 15% over 68 weeks.1 In SURMOUNT-1, tirzepatide produced average losses up to about 21% at the highest dose over 72 weeks — the FDA's approval summary describes an 18% average reduction relative to placebo at 15 mg.2,3 In the first head-to-head trial, published in 2025, tirzepatide averaged more loss than semaglutide.4
Averages are not promises. Some patients lose less, some more, and response cannot be fully predicted in advance. The job of a medical program is to maximize benefit while minimizing side effects, protecting lean mass, and monitoring the health markers that matter more than the scale.
Side effects and safety
The most common side effects are gastrointestinal — nausea, constipation, diarrhea, vomiting, reflux, abdominal discomfort — plus decreased appetite, fatigue, injection-site reactions, and hair shedding with rapid loss. They are usually dose-related and concentrated during escalation, which is exactly why escalation should be individualized rather than rushed.2
The serious considerations are a shorter but non-negotiable list: these medications are contraindicated with a personal or family history of medullary thyroid cancer or MEN 2, and carry warnings for pancreatitis, gallbladder disease, kidney injury from dehydration, hypoglycemia when combined with insulin or sulfonylureas, diabetic retinopathy in type 2 diabetes, and mood changes.2 We wrote a dedicated, unvarnished review of the risks and who shouldn't take GLP-1s — read it before starting anything.
Why medication alone under-delivers
A GLP-1 lowers appetite. It does not choose what you eat, hit a protein target, lift weights for you, fix your sleep, or plan what happens after the losing phase. Patients who eat very little of the wrong things lose weight and nutrients together. A complete program specifies protein intake, resistance training, hydration and fiber, constipation prevention, alcohol review, sleep, lab monitoring, body-composition tracking, dose adjustment, and side-effect management — in writing, with follow-up.
Muscle is the program's second job
Rapid weight loss takes lean mass along with fat — in the STEP 1 body-composition analysis, a substantial share of total loss was lean tissue.1 For patients over 40 this is the difference between ending up lighter and ending up healthier. The countermeasures are known and effective: adequate protein, progressive resistance training, a sane pace of loss, and monitoring. We cover the exact targets in how to keep your muscle on a GLP-1.
The maintenance question — asked on day one
In the STEP 1 extension, patients who stopped semaglutide regained about two-thirds of lost weight within a year.5 In SURMOUNT-4, patients switched from tirzepatide to placebo regained substantially while those who continued kept losing.6 This is not medication failure; it is what chronic disease does when treatment stops. Some patients will taper successfully with an aggressive lifestyle framework; many will need long-term therapy at some dose. Either way, the maintenance strategy should be designed at the start, not improvised at the end. For patients whose real goal is putting type 2 diabetes into remission, that strategy looks different again — see can type 2 diabetes go into remission?
A note on compounded GLP-1s
During the shortage years, compounded copies were legally permitted as a stopgap. That window has closed: the FDA declared the tirzepatide shortage resolved in December 2024 and semaglutide in February 2025, after which compounders were required to wind down copies of these drugs.8 Compounded products are not FDA-reviewed for safety, effectiveness, or quality. Our position is simple: know exactly what you are injecting, obtained through legitimate medical channels — anything else is a risk we do not recommend taking.
Frequently asked questions
How do GLP-1 medications work?
They act on incretin hormone pathways that regulate appetite, satiety, gastric emptying, and blood sugar. Most patients describe less hunger and far less constant thinking about food.1
Is semaglutide the same as tirzepatide?
No. Semaglutide is a GLP-1 receptor agonist; tirzepatide acts on both GIP and GLP-1 receptors and produced greater average weight loss in the head-to-head trial. Which is right for you depends on your history, indications, tolerance, and access.4
Do I need to stay on a GLP-1 forever?
Not always — but stopping without a maintenance plan usually leads to substantial regain, because obesity behaves as a chronic condition. A supervised program plans maintenance from the beginning.5,6
Can GLP-1s help with sleep apnea?
Tirzepatide (Zepbound) was FDA-approved in December 2024 for moderate-to-severe obstructive sleep apnea in adults with obesity, after trials showed large reductions in breathing disruptions alongside weight loss.9,10
What makes a physician-supervised GLP-1 program different?
Baseline labs and screening, individualized dosing, side-effect management, protein and training targets, body-composition tracking, and a maintenance strategy. The goal is better metabolic health — not just a smaller number on the scale.
GLP-1 treatment at Oriva Health
When a GLP-1 medication is appropriate, it comes as part of a physician-run metabolic program: full evaluation first, honest discussion of risks, muscle-preserving nutrition and training, structured lab follow-up, and a maintenance plan from the start. If that is the kind of care you want, we should talk.
Request more informationReferences
- Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384(11):989–1002.
- US Food and Drug Administration. FDA approves new medication for chronic weight management (Zepbound/tirzepatide). November 8, 2023.
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205–216.
- Aronne LJ, Horn DB, le Roux CW, et al. Tirzepatide as compared with semaglutide for the treatment of obesity (SURMOUNT-5). N Engl J Med. 2025;393(1):26–36.
- Wilding JPH, Batterham RL, Davies MJ, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553–1564.
- Aronne LJ, Sattar N, Horn DB, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA. 2024;331(1):38–48.
- Novo Nordisk. FDA approval of oral semaglutide 25 mg (Wegovy pill) for weight management. December 22, 2025.
- US Food and Drug Administration. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. 2025.
- Malhotra A, Grunstein RR, Fietze I, et al. Tirzepatide for the treatment of obstructive sleep apnea and obesity (SURMOUNT-OSA). N Engl J Med. 2024;391(13):1193–1205.
- US Food and Drug Administration. Approval of Zepbound (tirzepatide) for moderate-to-severe obstructive sleep apnea in adults with obesity. December 20, 2024.